Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Real-time Estimate Cboe BZX
Other stock markets
 03:47:44 2024-04-29 pm EDT 		5-day change 1st Jan Change
9.41 USD +2.51% Intraday chart for Phathom Pharmaceuticals, Inc. +4.11% +2.74%
Mar. 07 Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Mar. 07 Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating
MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating
MT
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target
MT
Craig-Hallum Starts Phathom Pharmaceuticals at Buy With $21 Price Target
MT
BMO Capital Adjusts Price Target on Phathom Pharmaceuticals to $30 From $35, Maintains Outperform Rating
MT
Needham Adjusts Price Target on Phathom Pharmaceuticals to $23 From $25, Maintains Buy Rating
MT
BMO Capital Trims Price Target on Phathom Pharmaceuticals to $35 From $38, Affirms Outperform Rating
MT
Needham Adjusts Phathom Pharmaceuticals Price Target to $25 From $38, Maintains Buy Rating
MT
BMO Capital Cuts Price Target on Phathom Pharmaceuticals to $38 From $45, Maintains Outperform Rating
MT
Guggenheim Adjusts Price Target on Phathom Pharmaceuticals to $30 From $42, Maintains Buy Rating
MT
Jefferies Starts Phathom Pharmaceuticals at Buy With $16 Price Target
MT
Needham Adjusts Phathom Pharmaceuticals' Price Target to $38 from $44, Keeps Buy Rating
MT
Goldman Sachs Adjusts Price Target for Phathom Pharmaceuticals to $15 From $32, Retains Neutral Rating
MT
PHATHOM PHARMACEUTICALS : Guggenheim Adjusts Phathom Pharmaceuticals PT to $75 From $66, Maintains Buy Rating
MT
PHATHOM PHARMACEUTICALS : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40
MT
PHATHOM PHARMACEUTICALS : BMO Capital Starts Phathom Pharmaceuticals at Outperform With $63 Price Target
MT
PHATHOM PHARMACEUTICALS : Guggenheim Starts Phathom Pharmaceuticals at Buy With $60 Price Target
MT
PHATHOM PHARMACEUTICALS : Needham Adjusts Phathom Pharmaceuticals' Price Target to $55 from $45, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. News Phathom Pharmaceuticals, Inc.
  5. Analyst Reco.